Kilde:Molbase:https://jiage.molbase.cn/kuaibao/525/125272 2022-03-09
Den 8. marts annoncerede Lonza færdiggørelsen af en laboratorieudvidelse på sit produktionssted for aktive farmaceutiske ingredienser (API) i Nansha, Kina. Udvidelsen fokuserer på at udvide kapaciteten i udviklingslaboratoriet og kilogram cGMP-produktionslaboratoriet for at levere en klinisk forsyning af effektive API (HPAPI).
HPAPI represents an increasing portion of the small molecule pipeline with special requirements for equipment, process safety, containment and facility design.HPAPI currently forms a large part of Lonza's small molecule development pipeline, and the need for manufacturing is growing.The new laboratory is part of a recent investment aimed at expanding the medium manufacturing capacity of the Nansha (CN) plant and adding additional capacity to Lonza's global HPAPI manufacturing network to meet growing customer needs.
Jan Vertommen, Executive Director of Lonza Small Molecule Commercial Development, commented: "With more than 1,000 HPAPI in development, covering a wide range of indications, there is a growing demand for HPAPI development and manufacturing capabilities from early stage to commercialization.The new lab further strengthens our global HPAPI manufacturing services and we are pleased that our first customers in Europe and the United States have signed up for the HPAPI program for our new lab in Nansha."
The new lab further strengthens our global HPAPI manufacturing services and we are pleased that our first customers in Europe and the United States have signed up for the HPAPI program for our new lab in Nansha."The new lab will begin operations in March 2022.
Jason Zhang, Lonza's Director of small molecule API research and development, added: "The expansion of our HPAPI capabilities in Nansha enables us to enter HPAPI manufacturing to meet the growing global demand, especially in supporting oncology clinical trials.Our presence in Nansha allows us to leverage world-class, quality and reliable local suppliers of raw materials, thus further increasing the speed of problem solving and manufacturing."
Den udvidede kapacitet hos Nansha vil fortsat støtte os i at udvikle og fremstille innovative behandlinger til vores globale kunder og deres patienter.
Netværkskilde, krænkelse kontakt venligst slet
